Novo Nordisk

Historical price data

Novo Nordisk's mission is to defeat diabetes and other serious chronic diseases through innovative biopharmaceutical solutions. The company has achieved transformative success with its GLP-1-based therapies, Ozempic® and Wegovy®, catalyzing a new era in metabolic care and generating massive commercial growth. Its strategy is built on expanding the clinical utility of its core platforms, advancing a deep pipeline of next-generation multi-agonists and novel modalities, and scaling manufacturing to meet global demand. Recent milestones include the US approval of the first once-weekly basal insulin, Awiqli®, and promising Phase 2 data for a triple agonist.

Proprietary platforms for protein/peptide engineering, GLP-1 receptor agonism, advanced drug delivery (including oral peptides), and emerging RNAi (GalXC) and antisense oligonucleotide (ASO) technologies.